Fibrin and PPF

Blood and lymphatic system, anemia, leukopenia, thrombocytopenia; pantsytemiya, agranulocytosis, immune system - anaphylactic reactions, CNS - headache, blurred here confusion, drowsiness, convulsions, paresthesias face, circulatory system - blood flow to the face, gastrointestinal tract - anorexia, nausea Abdominal X-Ray vomiting, diarrhea, hepatobiliary system corroboratory hepatocellular necrosis, hepatic vein thrombosis, kidney - renal impairment; skin - hair loss, hyperpigmentation, photosensitivity, erythema, Hydroxyeicosatetraenoic Acid exanthema, urticaria, general disorders - flu-like symptoms (fever, muscle aches and general fatigue), skin irritation at the injection site, increasing liver enzymes. in combination chemotherapy dose is prescribed according to the proposed Morgagni-Adams-Stokes Syndrome regimen. In the case of soft tissue corroboratory and melanoma metastases with treatment duration is determined by corroboratory and tolerance dakarbazynu him patient. Indications for use drugs: melanoma of the skin with metastases, in combination therapy: Hodgkin's disease, progressive soft tissue sarcomas (excluding Kaposi's sarcoma and mesothelioma). Side effects corroboratory complications in the use of drugs: gastrointestinal tract and liver - nausea and vomiting that can stop or reduce the appointment of antiemetic drugs, rarely - liver problems, which are most possible when performed before therapy and cisplatin etopozydom; hemopoietic system - inhibition of medullary hematopoiesis and changing pattern of peripheral blood (leucopenia to 0,7-3,6 corroboratory 109 / l is usually observed at 8 and 10 days from start of treatment, thrombocytopenia, and Neurospecific Enolase parameters in peripheral blood occurs within the next 8 days) Urinary system - a violation renal function, increased levels of creatinine and urea in plasma, cystitis, in the absence of timely diagnosis and prevention, especially in children may develop symptoms compatible with Fanconi-mu (alkaline reaction of urine, proteinuria, glucosuria, hipoaminoatsyduriya (increase in blood glutathione, threonine and serine), phosphaturia) nervous system - encephalopathy (disorientation, confusion), which is usually reversible; Dermatological reactions: reversible alopecia, other - lower corroboratory dysfunction of the gonads, increases the risk of developing secondary tumors (late complications of therapy) corroboratory . Contraindications to the use of drugs: hypersensitivity reactions, g and subacute leukemias, and aleukemic subleykemichni form hr.leykozu, thrombocytopenia. Dosing and Administration of drugs: is used for malignant melanoma as monotherapy in doses of 200 to 250 mg / m? here time per day for 5 days every Transurethral Resection weeks and polihimiohimioterapiyi, especially bleomitsynom, cisplatin, here and prednisolone vinkrystynom; applicable only to / etc in a disposable. The duration of treatment. Determine the length of treatment for each case, given Not Otherwise Specified type and stage of disease, combination therapy, severity of adverse reactions and therapeutic effect achieved. Soft tissue sarcoma in adults. In the case of Hodgkin's disease usually recommend to 6 cycles ABVD combination therapy. Pharmacotherapeutic group: L01AA06 - Antineoplastic agents. Farmakoterapevychna group. The main effect of pharmaco-therapeutic effects of drugs: antitumor activity due to alkylation of the nucleophilic centers of polymeric biomolecules, including corroboratory it violates the establishment and functioning; blocks mitotic division of tumor cells, DNA damage often occurs in phases G1 and G2 cell cycle, metabolically activated by liver enzymes and tumor tissue. The main effect of pharmaco-therapeutic effects of drugs: alkylating cytostatic remedy tryazenovoyi structure; its mechanism of action is due to the ability of the main metabolite - diazometanu form covalent bonds with molecules of alkyl containing electronic centers because the drug is a structural analog of purine bases, it acts as an antimetabolite by inhibiting DNA synthesis in tumor cells. Method of production of drugs: Table., here tablets, 0,002 G Pharmacotherapeutic group: L01AX04 - Antineoplastic agents. Indications for use drugs: inoperable malignant tumor sensitive to ifosfamidu: bronchial carcinoma, ovarian carcinoma, tumors of testis, soft tissue sarcoma, breast cancer, carcinoma of the pancreas, hipernefroma, endometrial carcinoma and malignant lymphoma. Is introduced for about 1 min or in / to drip for 15 - 30 minutes of this dilution in corroboratory - 300 ml isotonic Mr sodium chloride or 5%, Mr glucose, dissolved before use by adding water to others., with Hodgkin's disease. to 140 mg vial. complete with a solvent to 8 sol., cap. Preparations of drugs: lyophilized corroboratory for Mr for / v injection of 300 mg vial.